Home/Filings/4/0001415889-24-025354
4//SEC Filing

Enavate Sciences GP, LLC 4

Accession 0001415889-24-025354

CIK 0001736730other

Filed

Oct 16, 8:00 PM ET

Accepted

Oct 17, 4:15 PM ET

Size

11.5 KB

Accession

0001415889-24-025354

Insider Transaction Report

Form 4
Period: 2024-10-15
Transactions
  • Purchase

    Common Stock

    2024-10-15$11.00/sh+1,363,636$14,999,9963,785,802 total(indirect: By Everest Aggregator, LP)
  • Conversion

    Common Stock

    2024-10-15+2,422,1662,422,166 total(indirect: By Everest Aggregator, LP)
  • Conversion

    Series B Preferred Stock

    2024-10-1527,166,5300 total(indirect: By Everest Aggregator, LP)
    Common Stock (2,422,166 underlying)
Transactions
  • Conversion

    Common Stock

    2024-10-15+2,422,1662,422,166 total(indirect: By Everest Aggregator, LP)
  • Purchase

    Common Stock

    2024-10-15$11.00/sh+1,363,636$14,999,9963,785,802 total(indirect: By Everest Aggregator, LP)
  • Conversion

    Series B Preferred Stock

    2024-10-1527,166,5300 total(indirect: By Everest Aggregator, LP)
    Common Stock (2,422,166 underlying)
Footnotes (2)
  • [F1]Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
  • [F2]Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Issuer

Camp4 Therapeutics Corp

CIK 0001736730

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001953107

Filing Metadata

Form type
4
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 4:15 PM ET
Size
11.5 KB